Anti-CD30 monoclonal antibody BerH2

Drug Profile

Anti-CD30 monoclonal antibody BerH2

Alternative Names: BerH2 antibody

Latest Information Update: 05 Sep 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medac; Nonindustrial sources
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD30 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hodgkin's disease

Most Recent Events

  • 30 Nov 1999 Antibody development agreement signed with Medarex
  • 16 Dec 1998 New profile
  • 16 Dec 1998 Phase-I clinical trials for Hodgkin's disease in Germany (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top